LHLeonard R. Henry

Leonard R. Henry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leonard R. Henry has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Translational advances regarding hereditary breast cancer syndromes

    by M. Gage, D. Wattendorf, L.R. Henry

    Approximately 5–10% of breast cancers may be inheritable, up to 90% of which are due to mutations in BRCA1 and BRCA2. A substantial minority are caused by non‐BRCA mutations, such as TP53, PTEN, STK11, CHEK2, ATM, BRIP1, and PALB2 mutations. This review highlights translational research advances with regard to the development of probabilistic models for hereditary breast cancer syndromes, the identification of specific genetic mutations responsible for these syndromes, as well as their testing and interpretations. J. Surg. Oncol. 2012; 105:444–451.


  • Open Access

    Axillary sentinel lymph node biopsy after mastectomy: a case report

    by Diego A Vicente, Leonard R Henry, George Hahm, Peter W Soballe, DeeDee Smart

    Sentinel lymph node biopsy has been established as the preferred method for staging early breast cancer. A prior history of mastectomy is felt to be a contraindication.


  • Functional voice outcomes after thyroidectomy: An assessment of the Dsyphonia Severity Index (DSI) after thyroidectomy

    by Leonard R. Henry, Leah B. Helou, Nancy Pearl Solomon, Robin S. Howard, Joyce Gurevich-Uvena, George Coppit, Alexander Stojadinovic


  • Open Access

    Development of a clinical decision model for thyroid nodules

    by Alexander Stojadinovic, George E Peoples, Steven K Libutti, Leonard R Henry, John Eberhardt, Robin S Howard, David Gur, Eric A Elster, Aviram Nissan

    Thyroid nodules represent a common problem brought to medical attention. Four to seven percent of the United States adult population (10–18 million people) has a palpable thyroid nodule, however the majority (>95%) of thyroid nodules are benign. While, fine needle aspiration remains the most cost effective and accurate diagnostic tool for thyroid nodules in current practice, over 20% of patients undergoing FNA of a thyroid nodule have indeterminate cytology (follicular neoplasm) with associated malignancy risk prevalence of 20–30%. These patients require thyroid lobectomy/isthmusectomy purely for the purpose of attaining a definitive diagnosis. Given that the majority (70–80%) of these patients have benign surgical pathology, thyroidectomy in these patients is conducted principally with diagnostic intent. Clinical models predictive of malignancy risk are needed to support treatment decisions in patients with thyroid nodules in order to reduce morbidity associated with unnecessary diagnostic surgery.


  • The influence of a Gene expression profile on breast cancer decisions

    by Leonard R. Henry, Alexander Stojadinovic, Sandra M. Swain, Sheila Prindiville, Rose Cordes, Peter W. Soballe

    Purpose: The Oncotype Dx® Recurrence Score (RS), is often employed in patients with estrogen receptor‐positive, node negative (ER+LN−) breast cancer. We investigated the impact of the RS on actual chemotherapy administration and the effect of the assay on a panel of breast oncology experts.Patients and Methods: The prospective adjuvant chemotherapy recommendations (prior to RS) and actual adjuvant therapy (after RS) for consecutive patients with ER+LN− breast cancer were recorded. After 6 months and with the same information, a panel of five experts made adjuvant therapy recommendations with and without RS and rated the strength of their recommendations. Rates of panel consensus, recommendation changes, and changes in recommendation strength were compared.Results: There were 29 patients (28 women). RS results altered the plan for chemotherapy in 9 patients (31%); 7 of 13 patients (54%) initially recommended for chemotherapy did not receive it, and 2 of 16 (13%) received chemotherapy following initial recommendations against it. RS results changed the panel's chemotherapy recommendation in 7 patients (24%): 5 of 12 (42%) recommendations for changed to against, and 2 of 17 (12%) recommendations against changed to for chemotherapy. RS increased consensus by the panel 10%, but did not increase the reported strength in chemotherapy recommendations.Conclusions: RS results were associated with real‐world decision changes in 31% of patients and 24% of panel recommendations and increased panel consensus by 10%. However RS did not increase the strength of panelist's recommendations. J. Surg. Oncol. 2009;99:319–323. Published 2009 Wiley Periodicals, Inc.